



Cite this article: Tinti M, Johnson C, Toth R, Ferrier DEK, MacKintosh C. 2012 Evolution of signal multiplexing by 14-3-3-binding 2R-ohnologue protein families in the vertebrates. *Open Biol* 2: 120103. <http://dx.doi.org/10.1098/rsob.120103>

Received: 18 June 2012

Accepted: 29 June 2012

Subject Area:

biochemistry/bioinformatics/developmental biology/systems biology

Keywords:

Branchiostoma, *Ciona*, hereditary spastic paraplegia, RAB3GAP1, RAB3GAP2

Author for correspondence:

Carol MacKintosh

e-mail: c.mackintosh@dundee.ac.uk

[†]These authors contributed equally to this study.

Electronic supplementary material is available at <http://dx.doi.org/10.1098/rsob.120103>.

Evolution of signal multiplexing by 14-3-3-binding 2R-ohnologue protein families in the vertebrates

Michele Tinti^{1,†}, Catherine Johnson^{1,†}, Rachel Toth¹,

David E. K. Ferrier² and Carol MacKintosh¹

¹MRC Protein Phosphorylation Unit, College of Life Sciences, James Black Centre, University of Dundee, Dow Street, Dundee DD1 5EH, UK

²Evolutionary Developmental Genomics Group, The Scottish Oceans Institute, University of St Andrews, East Sands, St Andrews KY16 8LB, UK

1. Summary

14-3-3 proteins regulate cellular responses to stimuli by docking onto pairs of phosphorylated residues on target proteins. The present study shows that the human 14-3-3-binding phosphoproteome is highly enriched in 2R-ohnologues, which are proteins in families of two to four members that were generated by two rounds of whole genome duplication at the origin of the vertebrates. We identify 2R-ohnologue families whose members share a 'lynchpin', defined as a 14-3-3-binding phosphosite that is conserved across members of a given family, and aligns with a Ser/Thr residue in pro-orthologues from the invertebrate chordates. For example, the human receptor expression enhancing protein (REEP) 1–4 family has the commonest type of lynchpin motif in current datasets, with a phosphorylatable serine in the –2 position relative to the 14-3-3-binding phosphosite. In contrast, the second 14-3-3-binding sites of REEPs 1–4 differ and are phosphorylated by different kinases, and hence the REEPs display different affinities for 14-3-3 dimers. We suggest a conceptual model for intracellular regulation involving protein families whose evolution into signal multiplexing systems was facilitated by 14-3-3 dimer binding to lynchpins, which gave freedom for other regulatory sites to evolve. While increased signalling complexity was needed for vertebrate life, these systems also generate vulnerability to genetic disorders.

2. Introduction

Around 500 Ma, the vertebrates emerged from a massive evolutionary upheaval that involved two rounds of whole genome duplication (2R-WGD), with additional subsequent WGDs in certain lineages of bony fish and amphibians. Compelling evidence for these events emerged only recently, when the genomic signatures of the 2R-WGD were traced from invertebrates through to humans and other vertebrates [1,2]. A key new data source is the genome sequence of amphioxus (lancelet, *Branchiostoma*), the least-derived living invertebrate relative of the vertebrates within the phylum Chordata. Protein-coding gene duplicates that stem from the 2R-WGD are termed 2R-ohnologues. Generally, amphioxus has one 'ancestral' protein for each human 2R-ohnologue family. However, losses mean that only 15 to 30 per cent of genes in modern-day humans still belong to 2R-ohnologue families containing two to four members [1,2]. This raises several important questions: why did only certain gene

duplicates survive? How did they shape vertebrate evolution? And what is their impact on human health and diseases?

Lists of human 2R-ohnologues were compiled recently and mapped onto datasets of genes that underpin biochemical events and diseases [2–4]. The human 2R-ohnologues were found to be less likely than non-ohnologues to have undergone subsequent small-scale duplications. This finding is consistent with the concept that present-day 2R-ohnologues have been maintained in dosage-balanced sets. Each of these sets is thought to contribute to a common process or structure that would be upset by changing the level of one or a few components [2]. Strikingly, many 2R-ohnologue families include Mendelian disease genes, which is also in line with the gene–dosage balance hypothesis [2,4,5]. Human 2R-ohnologues are also enriched in components of growth factor and developmental signalling pathways, and preferentially expressed in the nervous system and in vertebrate-specific organs [3]. The overall impression is that balanced sets of 2R-ohnologue families supported the evolution of vertebrate specialities, while also introducing vulnerability to genetic diseases.

In addition to the hypothesized retention of 2R-ohnologues owing to dosage-balance, it is thought that duplicate genes are often retained when they diverge to gain new functions (neofunctionalization) or partition subfunctions of their ancestral gene between the duplicates [6,7]. However, domain architectures are often conserved across 2R-ohnologue families, so it seems likely that functional genetic divergence may occur in the linker sequences between the domains, which tend to evolve faster than the functional domains and are enriched in regulatory phosphorylation sites [8].

Phosphorylated motifs are conserved to different degrees within protein families and across species. Some regulations require a precisely positioned phosphorylation, whereas in other cases the density of charge matters more than position [8–13]. Many phosphorylated residues dock onto regulatory proteins whose specificities may further constrain the evolution of the phosphoprotein.

The eukaryotic 14-3-3s comprise one such family of phosphoprotein-binding proteins. Their name refers to their discovery as proteins in fraction 14-3-3 in a sequential DEAE–cellulose and starch–gel separation of brain extract. 14-3-3s are dimers that dock onto specific pairs of phosphorylated serine and threonine residues on many proteins. These targets include human proteins that are linked to metabolic and neurological disorders, and to cancer [14]. By docking onto two phosphorylated residues that may be phosphorylated by different kinases, a 14-3-3 dimer can act as a logic gate that integrates two inputs. The bound 14-3-3 dimer may mask a functional domain in the target protein, or induce a conformational change [14–17]. Thus, a 14-3-3 dimer is a protein device that integrates two kinase signalling inputs and exerts a mechanical action on the target.

14-3-3-binding motifs generally have at least one basic residue in the –3 to –5 positions relative to the phosphorylated serine or threonine, and never a +1 proline [14,17]. Such sequences are phosphorylated by AGC (protein kinase A/protein kinase G/protein kinase C family) and CAMK (Ca²⁺/calmodulin-dependent protein kinase) protein kinases, including PKA (protein kinase A), Akt/PKB (protein kinase B), SGK (serum and glucocorticoid-regulated kinase), p90RSK (90 kDa ribosomal protein S6 kinase), PKCs (protein kinase C family members) and AMPK (AMP-activated protein kinase)

[18]. Therefore, 14-3-3s mediate cellular responses to insulin, growth factors and other stimuli that activate these kinases [14,19].

Recent studies of two sister Rab-GTPase activating proteins (AS160/TBC1D4 and TBC1D1) that regulate glucose uptake into muscles inspired speculation that 14-3-3 dimers could provide an evolutionary mechanism for the regulatory divergence of their targets [14]. AS160 and TBC1D1 each contain two 14-3-3-binding sites: one site is similar in both proteins, but the second site differs between them. The 14-3-3-binding site common to each protein is an insulin-regulated Akt/PKB-phosphorylated site. The second site on AS160 is phosphorylated by Akt/PKB and p90RSK, whereas on TBC1D1 it is phosphorylated by kinases including AMPK, which is activated in energy-depleted cells [20–22]. It is therefore inferred that AS160 and TBC1D1 have complementary roles in regulating glucose homeostasis in response to insulin and energy stress, respectively [23].

Accordingly, we proposed the lynchpin hypothesis. Suppose that an ancestral 14-3-3-binding protein were duplicated. Then, if one 14-3-3-binding site remained unchanged, it could provide a ‘lynchpin’ whose binding to a 14-3-3 dimer might provide sufficient intracellular control to permit the second 14-3-3-binding site to evolve into a consensus for phosphorylation by a different protein kinase. The result would be two proteins with the same function, but regulated by different signalling inputs [14].

Here, we wished to progress from an anecdotal to a more systematic analysis. Therefore, we classified human proteins for which 14-3-3-binding sites have been reported, and discovered that the majority are also 2R-ohnologues. Sequence alignments indicated interesting patterns of conservation and divergence of 14-3-3-binding sites across 2R-ohnologue families. We investigated these in the REEP protein family, which includes the Hereditary Spastic Paraplegia 31 protein REEP1. Our findings have implications for understanding the evolution of vertebrates, and also for certain neurodevelopmental disorders, metabolic diseases and cancer. Further, we suggest a conceptual model for considering intracellular regulation in terms of multiple-input multiple-output (MIMO) array systems.

3. Results

3.1. Most well-defined human 14-3-3-binding proteins are 2R-ohnologues

Two published lists of human 2R-ohnologues overlap by 6374 genes [2,3], with a further 920 genes uniquely assigned as 2R-ohnologues in one study [2] and 3096 in the other [3] (figure 1a). Much of the difference is due to a larger number of families of five or more genes being counted as 2R-ohnologues in the latter study. By definition, a 2R-ohnologue family is not expected to contain more than four protein-coding genes, unless there have been further duplications after the 2R-WGD. Thus, when there are insufficient data to sort larger families of paralogues into their respective 2R-ohnologue subsets, these have been left unresolved as families of five or more as a temporary measure (figure 1a).

Genes from these two studies were matched to the corresponding human proteins with UniProt identifiers. In this way, 7104 [2] and 9367 [3] out of the 20 244 non-redundant




Figure 1. Enrichment of 2R-ohnologues among well-defined 14-3-3-binding phosphoproteins. (a) 2R-ohnologues in the human proteome. Two published 2R-ohnologue gene datasets (PNAS, green) [2] and (BMC, blue) [3] were transcribed onto the human proteome (20 244 proteins in UniProt release 08-2011), and plotted according to 2R-ohnologue protein family sizes assigned in [2] and [3] (see the electronic supplementary material, table S2). The Venn diagram depicts the overlap of 2R-ohnologues assigned by the two studies. (b) Gold and silver 14-3-3-binding protein 2R-ohnologue families. Up to August 2011, 172 gold standard (GD) proteins with defined 14-3-3-binding phosphosites had been identified, while a further 35 are silver standards (SL) whose direct phosphorylation-dependent binding to 14-3-3 has been demonstrated but the relevant sites not pinpointed [14,24] (electronic supplementary material, table S1). These 207 proteins were assigned into 2R-ohnologue families of 2, 3, 4 and 5 or more proteins according to the assignments in (a) (green and blue, as before). In red are the 2R-ohnologue families assigned in this study by abbreviated forms of the procedures given for the REEP proteins in figures 4 and 5. The hypergeometric probabilities of the observed distributions occurring by chance are indicated. For the manually curated data (this study), the two hypergeometric probabilities represent comparisons with the whole proteome datasets from [2] and [3], respectively.

human proteins could be assigned to 2R-ohnologue families of two or more proteins (figure 1a).

There are 172 ‘gold standard’ human proteins with well-defined 14-3-3-binding sites, and a further 35 ‘silver standards’ for which direct phosphorylation-dependent binding to 14-3-3s has been demonstrated, but relevant phosphosites not yet pinpointed [14,24] (electronic supplementary material, table S1). We compared this list of 207 14-3-3-binding proteins with the published 2R-ohnologue lists [2,3], and also with a 2R-ohnologue list that we compiled by performing phylogenetic and gene synteny analyses for every 14-3-3-binding protein (examples of such analyses are given later). Strikingly, approximately 84 per cent (174/207) of gold and silver

14-3-3-binding proteins are 2R-ohnologues, belonging to 139 protein families with a total of 525 family members (figures 1b and 2; electronic supplementary material, table S2). Therefore, compared with human proteins in general (figure 1a), the 14-3-3-binding phosphoproteome is highly enriched in membership of 2R-ohnologue families (figures 1b and 2).

3.2. Using 2R-ohnologue datasets to help create a priority list for validation of high-throughput 14-3-3-capture experiments

In addition to gold and silver 14-3-3-binding proteins, 1772 proteins had been isolated from mammalian cell and tissue lysates by 14-3-3-affinity capture in 16 high-throughput (HTP) proteomics experiments up to August 2010 (figure 3a) [24]. It is therefore imperative to sort these proteins into a manageable priority list for the future determination of which are true 14-3-3-interactors; which bind indirectly to 14-3-3s as components of multi-subunit complexes; and which proteins had been isolated because they bind non-specifically to affinity matrices. The overlap between these HTP experiments and 2R-ohnologues is approximately 825 proteins, in 564 families with a total of 2023 members (figure 3b). Given the striking enrichment of 2R-ohnologues among the well-defined 14-3-3-binding proteins (figures 1b and 2), we suggest that the 2R-ohnologues from the HTP screens should receive priority attention.

As an additional way to filter potential non-specific hits from the HTP 14-3-3 proteomics datasets, we prepared an ‘exclusion list’ of potential contaminants using data provided by colleagues, who had isolated proteins from human cell lysates using ‘control’ beads or ligands unrelated to 14-3-3s. Interestingly, there is a relatively clean separation between the gold and silver 14-3-3-binding proteins, and these contaminants (see figure 3a; electronic supplementary material, table S3). Applying the 2R-ohnologues as an ‘inclusion list’ and the common contaminants as ‘exclusion list’ to the proteins identified in HTP 14-3-3 proteomics screens resulted in a list of 750 proteins that represent 538 families with a total of 1929 members (see electronic supplementary material, table S3).

In summary, while the numbers are impossible to predict precisely, there are strong indications that the total overlap between 2R-ohnologues and 14-3-3-binding phosphoproteins may be substantial, and it may be helpful to focus on this subset when selecting candidates for biochemical experiments.

3.3. Disease associations of 2R-ohnologue families that include 14-3-3-binding proteins

An association between 2R-ohnologues and human genetic disease has already been pointed out [2]. Here, we examined the disease associations of 2R-ohnologue families that contain the gold and silver 14-3-3-binding proteins, and found that a striking 91 per cent of these families (127 out of 139) and 64 per cent of the 2R-ohnologue proteins (350/525) are associated with a disease; developmental, cancer and psychiatric were the most represented disease categories (see electronic supplementary material, table S2 and figure S1). Interestingly, for 76 families, different members of the same family




Figure 3. Visualization of the mapping of 2R-ohologue families onto the 14-3-3 interactome. (a) A graph created using VisANT (visant.bu.edu) [30], from the data collated in electronic supplementary material, table S2, shows the overlapping sets of proteins that were isolated from mammalian cells in 16 HTP 14-3-3-affinity capture experiments published up to August 2010 [24]. Each study was assigned a node in blue and lines connect these articles to the identified proteins, depicted with a default of green circle nodes. Then, well-defined gold and silver standard 14-3-3-binding proteins (see the electronic supplementary material, table S1) were changed from green to red. Proteins from the ‘common contaminants’ list (electronic supplementary material, table S3) were changed to black. Thereafter, proteins were assigned to 2R-ohologue families, which were depicted as rectangles whose internal structure is described in panel (c). The interactive version of this graph is available under 14-3-3 partners at <http://www.ppu.mrc.ac.uk/research>. (b) (i) The overlap between the HTP 14-3-3 affinity capture experiments (a) and 2R-ohnologues is 825 proteins according to the 2R-ohologue assignment of [2]. (ii) Classification of these 825 2R-ohologue proteins into families of 2, 3, 4 and 5 or more proteins. (c) The box in (a) was expanded to visualize the REEP protein family members, which reveals that REEP3 had been identified in two HTP 14-3-3-affinity capture experiments, while REEP4 had been reported in one HTP experiment and had also achieved gold standard status by identification of a 14-3-3-binding phosphosite. The interactive version of the VisANT graph (a) reveals similar details for any protein or protein family by clicking on nodes on the graph, or entering the required UniProt protein name into a search box.




Figure 4. Gene synteny analysis of the vertebrate REEP 1–4 proteins. (a) Gene synteny clusters (paralogons) within the human genome were identified using only the human REEP1, REEP2, REEP3 and REEP4 genes as queries of the Synteny Database (http://teleost.cs.uoregon.edu/synteny_db/) [36] (left), with the search widened to include genes within 500 kb of these genes (right). (b) The diagram shows only those gene matches that can be traced across at least three paralogs. Though not to scale, chromosomal distances are indicated in megabases. The extent of the minimal 5q31.2 commonly deleted region 1 (CDR1) of myelodysplastic syndrome [35] is indicated. *Branchiostoma floridae* gene 185 339 is related to human REEPs 1–4; 269 996 is related to human EGR 1–3; and 124 949 to human HR, KDM3A, JMJD1C, KDM3B.

are linked with distinct disorders (see electronic supplementary material, table S2 and figure S1).

3.4. Evolutionary history of the human REEP proteins and their ‘lynchpin’ 14-3-3-binding site

To identify potential ‘lynchpins’, we determined how many published 14-3-3-binding phosphosites are conserved across the respective 2R-ohnologue family and align with serine or threonine residues in the corresponding pro-orthologues of the invertebrate chordates, namely *Branchiostoma* (amphioxus) and *Ciona* (tunicates). Not all sites could be assigned one way or another because many of the invertebrate protein sequences in the databases are incomplete. However, 103 experimentally defined sites in 76 protein families are conserved across the human protein family and find a matching serine or threonine in the sequences from the chordate invertebrates (see electronic supplementary material, table S2 and figure S2). One such conserved

potential ‘lynchpin’ is in the receptor expression enhancing protein (REEP) family (figure 3c, and later).

The six REEP proteins include REEP1, which is mutated in hereditary spastic paraplegia 31 (one of a group of disorders characterized by progressive weakness and stiffness of the legs), and REEP4, loss of which causes paralysis in *Xenopus* [31,32]. REEP proteins are tethered to the cytoplasmic face of the endoplasmic reticulum (ER) and contiguous membranes, and are implicated in ER morphology (as are the other hereditary spastic paraplegia proteins atlastin and spastin), mitochondrial function, and translocation of olfactory, taste and other receptors to the cell surface [33,34].

Phylogeny, gene synteny and sequence alignments indicate that two REEP genes in invertebrate chordates—185 339 and 57 028 (proteins C3ZZ30 and C3Z345) of *Branchiostoma floridae*—gave rise to two separate 2R-ohnologue families in vertebrates: REEPs 1–4 and REEPs 5–6, respectively. The latter, including the amphioxus pro-orthologue, lack the 14-3-3-binding region and are not considered further. Human REEPs 1–4 display the genetic signatures expected for a family derived from 2R-WGD and not from small-scale

tandem duplications. The four genes are located on different chromosomes (*REEP1* is at 2p11.2, *REEP2* lies within the myelodysplastic syndrome (MDS) 5q31.2 microdeletion [35], *REEP3* is at 10q21.3 and *REEP4* at 8p21.3), and the genes for human REEPs 1–4 are in chromosomal segments that share conserved neighbouring genes: that is, they reside in ‘paralogons’ (figure 4). The phylogenetic tree shows single invertebrate REEP genes clustering as a sister group to the clade of all four vertebrate paralogy groups. The tree topology is consistent with that expected if the first round of whole genome duplication (1R-WGD) gave rise to two genes, and then in the 2R-WGD one of these genes gave rise to *REEP1* and *REEP2*, whereas the other duplicated to make *REEP3* and *REEP4* (see figure 5a; electronic supplementary material, figure S3). Interestingly, *REEP4* is missing from the bony fish.

Ser152 of *REEP4* is a phosphorylated residue whose mutation to Ala prevents its binding to 14-3-3s in cell lysates, and which lies within a motif resembling a typical 14-3-3-binding site (RLRSF(s152)MQ, where the lower case ‘s’ is phosphorylated) [24]. All four human REEP proteins have a Ser that corresponds to Ser152, with minor variations at –5 (Lys in *REEP2*) and +2 (His in *REEP3*), and this residue is therefore a potential lynchpin (figure 5b). Variations on this 14-3-3-binding motif are found in the REEP orthologues of species within the Bilateria (figure 5b), and although phosphorylation cannot be inferred from sequence alone, this is consistent with the possibility that this 14-3-3-binding motif was in place in the chordates prior to the 2R-WGD at the origin of the vertebrates (figure 5b). All four vertebrate REEP proteins also have a –2 serine (Ser150 in *REEP4*) that is recorded as a phosphosite (www.phosphosite.org; figure 5b). Interestingly, the gold standard human 14-3-3-binding sites are enriched in phosphorylatable –2 serines, whereas other random sets of phosphorylated sites are not (see electronic supplementary material, figures S2 and S4).

3.5. Human REEP1, 2, 3 and 4 are differentially regulated by phosphorylation and 14-3-3s

To understand how sequence relates to function, we examined the regulation of REEPs 1–4 biochemically. We raised a phospho-specific antibody, which revealed that phosphorylation of Ser152 of *REEP4* was unaffected by various extracellular stimuli, including phorbol ester, and yet phorbol ester slightly increased the binding of 14-3-3s to *REEP4* (figure 6a). Moreover, Ser152Ala-*REEP4* mutant protein bound to 14-3-3 only in lysates of phorbol ester-stimulated cells, and this was blocked by the broad spectrum protein kinase C (PKC) inhibitor Gö6983, but not the PKC α and PKC β -selective inhibitor Gö6976, nor p90RSK inhibitor BI-D1870 (figure 6a). These data suggested the existence of a second 14-3-3-binding site on *REEP4*, which was phosphorylated by a PKC, or PKC-activated protein kinase other than p90RSK, in response to phorbol ester. Mutation of Ser224 decreased overall 14-3-3 binding to *REEP4* and prevented the phorbol ester stimulation of 14-3-3 binding (see figures 6b and 7; electronic supplementary material, figure S5). These data indicate that a 14-3-3 dimer binds to both phosphoSer152 and phorbol ester-regulated phospho-Ser224 on *REEP4* (figure 7a). Similar to *REEP4*, *REEP3* also binds to 14-3-3 via phosphoSer152 and Ser225 (see figures 6c and 7b; electronic supplementary material,

figure S5). Consistent with the cellular data, *in vitro* phosphorylation by PKC ζ enabled *REEP3* and *REEP4*, but not *REEP1* and *REEP2*, to bind to 14-3-3 (figure 6d(i)). Ser224 is the PKC ζ -phosphorylated site on *REEP4* since its mutation to alanine prevented PKC ζ -mediated 14-3-3 binding (figure 6d(ii)).

In contrast, the weak binding of 14-3-3 to *REEP1* was not regulated by PMA (see figure 6c; electronic supplementary material, figure S5), but was enhanced by treating cells with the protein phosphatase inhibitor calyculin A (not shown). Analysis of point mutants indicated that phosphoSer192 of *REEP1* is a second 14-3-3-binding site, which is phosphorylated by an unknown kinase (see electronic supplementary material, figure S5; figure 7b). *REEP2* did not bind significantly to 14-3-3, though it is phosphorylated on a serine residue analogous to *REEP4*-Ser152 (see figure 6c; electronic supplementary material, figure S5), and no second site on *REEP2* has yet been identified.

3.6. Human REEP4 binds to the RAB3GAP1–RAB3GAP2 heterodimer whose mutations underlie Warburg Micro and Martsolf syndromes

In addition to 14-3-3s, mass fingerprinting of Coomassie-stained gels and Western blotting of REEP-GFP proteins isolated from cell lysates showed that *REEP4* binds to RAB3GAP1 and RAB3GAP2 (figure 6b,c), which together form a heterodimeric GTPase-activating protein for the small GTPase Rab3. Mutations in RAB3GAP1 and RAB3GAP2 cause the neurodevelopmental Warburg Micro (OMIM 60018) and Martsolf (OMIM 21270) syndromes, respectively [38–40].

Intriguingly, RAB3GAP1 and RAB3GAP2 do not bind to Ser152Ala-*REEP4* (figure 6b,e). However, despite sharing Ser152 as a common binding determinant, the interactions of 14-3-3s and RAB3GAP1–RAB3GAP2 heterodimer with *REEP4* differ. In contrast to 14-3-3s, RAB3GAP1 and RAB3GAP2 bind to unphosphorylated *REEP4* (see electronic supplementary material, figure S5) and binding of RAB3GAP1 and RAB3GAP2 to *REEP4* was not decreased when acidic residues took the place of Ser152 (figure 6b). Also, Ser224Ala-substituted *REEP4* had enhanced binding to RAB3GAP1–RAB3GAP2, but almost no 14-3-3 interaction (figure 6b,e). Thus, 14-3-3s and the RAB3GAP1–RAB3GAP2 heterodimer must be in distinct *REEP4*-containing complexes.

Further analyses with a series of chimeric proteins that contain different combinations of parts of *REEP3* and *REEP4* indicated that the mid-region of *REEP4* binds to RAB3GAP1 and RAB3GAP2, whereas the C-terminal third of *REEP4* appears to be slightly inhibitory for RAB3GAP1–RAB3GAP2 binding (see electronic supplementary material, figure S5).

4. Discussion

4.1. The lynchpin hypothesis and evolution of signal multiplexing by 2R-orthologue families

Our data suggest a new conceptual model for intracellular regulation in terms of protein families that evolved into signal multiplexing systems in the vertebrates. We propose that the binding of 14-3-3 dimers to one phosphorylated




Figure 5. Phylogenetic tree of the vertebrate REEP 1–4 proteins and evolution of the lynchpin 14-3-3-binding phosphorylation site. (a) The phylogenetic tree of the vertebrate REEP 1–4 proteins shows the topology expected from the 2R-WGD events. Sequences were aligned using MAFFT within JALVIEW (<http://www.jalview.org/>). The neighbour-joining tree was constructed in PHYLIP (<http://evolution.genetics.washington.edu/phytip.html>), using the JTT model and 1000 bootstrap replicates. Numbers above the branches show the bootstrap support for that branch. Only values over 700 (i.e. 70%) are shown, except for the value uniting vertebrate REEP 3 and 4 groups, which falls just below this value (at 621). The tree is rooted with the non-metazoan choanoflagellate sequence from *Monosiga brevicolis* as the outgroup. The vertebrate REEP 1–4 proteins cluster with the four human proteins into four paralogy groups represented by triangles, with the expanded version given in electronic supplementary material, figure S3. (b) Sequence alignments with the ‘lynchpin’ 14-3-3-binding motif on human REEP 1–4 (Ser152 of REEP4). The lynchpin region of the human REEP 1–4 was aligned with corresponding sequences from selected metazoan species of the Bilateria, which comprise Deuterostomia (bottom nine sequences) and Protostomes (Ecdysozoa—three sequences shown; and Lophotrochozoa—four shown); and non-Bilaterian basal metazoans (top four sequences), according to the super-phylum classification outlined by Telford & Copley [37]. Serine and threonine residues that align with Ser152 of human REEP4 are in red, and basic residues that align with those in the 14-3-3-binding motif are in dark blue.




Figure 6. Differential regulation of vertebrate REEP 1–4 proteins. (a) Effect of different stimuli/inhibitor combinations on the cellular regulation of REEP4-GFP. HEK293 cells were transfected to express REEP4-GFP (wild-type) and REEP4-S152A-GFP, serum-starved for 8 h, then stimulated with or without inhibitors, as indicated. REEP4-GFP was isolated from cell lysates (anti-GFP IPs) and blotted with the antibodies indicated. Also, the ability of the GFP-REEP4 proteins to bind directly to 14-3-3 was tested with a 14-3-3 Far-Western assay. The blots of cell lysates (30 μ g) show the phosphorylation of Ser152 of REEP4, and efficacy of EGF and PMA in stimulating Erk phosphorylation, and forskolin in stimulating VASP phosphorylation. (b) Effect of mutations on interactions of REEP4 with other proteins. Wild-type REEP4-GFP or the single site mutant proteins indicated were isolated from HEK293 cell lysates and blotted with the antibodies shown, and probed in a Far-Western assay for direct binding to 14-3-3s. (As here, it is typical that Asp and Glu do not mimic phosphorylated residues with respect to 14-3-3 binding.) (c) Interaction of REEP proteins with 14-3-3, RAB3GAP1 and RAB3GAP2. The indicated REEP-GFP proteins were isolated from lysates of transfected cells (anti-GFP IP). Copurification of endogenous RAB3GAP1, RAB3GAP2 and 14-3-3 was detected by immunoblotting, and the ability of REEP proteins to bind directly to 14-3-3 was also tested by Far-Western assay. (d) PKC ζ phosphorylation and 14-3-3 binding of REEP1, 2, 3 and 4 *in vitro*. (i) GST-tagged REEP proteins (Y65-end, lacking the N-terminal membrane-binding regions) were expressed and purified from *Escherichia coli*, and phosphorylated *in vitro* with PKC ζ . Protein (500 ng) was analysed by 14-3-3 Far-Western assay to detect direct binding to 14-3-3s. (ii) Wild-type REEP4 and putative 14-3-3-binding site mutants were assessed for PKC ζ -mediated 14-3-3 binding. (e) Reciprocal interaction of RAB3GAP1 with REEP4. Endogenous RAB3GAP1 was immunoprecipitated from HEK293 cells transfected with plasmids to express wild-type or mutant forms of REEP4-GFP. The immunoprecipitates were blotted with the antibodies shown. A control immunoprecipitation was performed with pre-immune antibodies.




Figure 7. Signal multiplexing by 14-3-3-binding phosphoprotein families in the vertebrates. (a) The diagram depicts how a 14-3-3 dimer is envisaged to bind to REEP4 via phosphorylated Ser152, and also Ser224 that is phosphorylated in phorbol ester-stimulated cells. The N-terminal membrane-tethering hydrophobic hairpin is also indicated. (b) 14-3-3-binding sites of the human REEP proteins. Serine and threonine residues reported to be phosphorylated in the literature (www.phosphosite.org) and/or in this study are in lower case, and phosphorylated 14-3-3-binding residues are in bold: the lynchpin (phosphoSer152 in REEP4) is indicated by the symbol and second 14-3-3-binding sites in grey (pSer192 in REEP1, pSer225 in REEP3, pSer224 of REEP4). (c) A signal multiplexing system: this represents the scenario where a 2R-ohnologue family of 14-3-3-binding proteins (A to D) has evolved such that they each maintain a common lynchpin phosphorylation site for binding to 14-3-3 and have a variable second site, which can be phosphorylated by different kinases. Such multiplexers have considerable potential for regulatory variation: They could operate in multiple-input, multiple-output (MIMO) mode, or multiple-input, single-output (MISO) mode, generate graded output responses that increase in intensity as each target protein in the family is engaged, or be all-or-nothing devices that trigger an output only when every family member has been captured by a 14-3-3 dimer.

'lynchpin' provided freedom for other regulatory sites to change and be regulated by different kinases on different family members [24,41]. Even minor sequence changes have the potential to rewire the signalling inputs from protein kinases. For example, PKB/Akt and SGK create phosphorylated RxRxx(pS/pT) motifs, whereas p90RSK prefers to phosphorylate the serine within RxRxx(pS), and Lats kinases phosphorylate HxRxx(pS/pT) sites [42,43]. The resulting 2R-ohnologue protein families would enable a given process to be regulated by more signalling inputs than could be accommodated by a single protein (figure 7c). Such signal multiplexing is reminiscent of the powerful multiple-input, multiple-output (MIMO) signalling arrays that boost signal-to-noise ratios and communication flows in smart-phone networks.

Human 14-3-3-binding 2R-ohnologues include components of developmental and growth factor signalling pathways such as insulin-receptor substrate proteins, fibroblast growth factor receptors, Raf kinases and other protein kinase families [3], as well as many downstream target proteins that link these signalling pathways to the regulation of membrane trafficking, metabolism, the cell cycle and gene expression [44,45] (figure 2). The concept of MIMO arrays should therefore be a useful framework for understanding complexities of growth factor signalling pathways, including signal integration, feedback regulation, oncogene

addition and differential responses of different cell types. These ideas provide impetus to explore how the extra signal-streaming capacity of such MIMOs contributed to the evolution of complex vertebrate forms.

A special feature of vertebrate embryo development is that cells in the neural crest undergo an epithelial–mesenchymal transition (EMT) and migrate to different regions of the embryo, where they differentiate into a wide variety of cell types that contribute to craniofacial structures, heart valves, pigmented skin cells and many other vertebrate features. A reactivation of the EMT programme is thought to underlie the aggressive metastatic behaviours of cancers, such as melanoma. It is therefore interesting that key transcription factors that mediate the EMT and neural crest cell differentiation belong to 14-3-3-binding 2R-ohnologue families, including snail, MITF and TLX-2 [46–48].

We therefore suggest that neofunctionalization, in terms of divergence of regulatory phosphorylations and 14-3-3-binding specificities, made a greater contribution to 2R-ohnologue survival than has been realized. However, we do not reject paradigms of 2R-ohnologue retention driven by dosage balance and subfunctionalization. Indeed, the human 14-3-3s are themselves also 2R-ohnologues, which suggest that 14-3-3s coevolved with their targets, in line with the gene–dosage balance hypothesis. The concept of gene–dosage was developed for smaller pathways and

complexes, and understanding how it applies to the human 14-3-3-interactome will require the emergent properties of the whole network to be defined. Efforts in this direction are under way. For example, proteomics experiments are identifying which proteins are phosphorylated and captured by 14-3-3s in response to different extracellular stimuli [44,45].

The singleton human 14-3-3 targets also went through the WGD events before being returned to singleton status by gene-loss mutations in all but one of the paralogues. For the species to survive, 14-3-3 signalling had still to be viable throughout these changes in gene-dosage, but perhaps these proteins were more efficient as singletons. It may be significant that several 14-3-3-binding singletons belong to ancient multi-protein complexes: Rictor, raptor and PRAS40/AKT1 are in the nutrient-sensing mTOR (mammalian target of rapamycin) complexes; BAD and B2L11 are central components of the apoptotic machinery; and EDC3 (enhancer of mRNA-decapping protein 3) is part of an mRNA-decapping complex [44,45]. Also, 14-3-3-binding sites in two singletons are ancient, one in the human transcriptional repressor capicúa is conserved in the *Drosophila* protein [49], and the mammalian (PI4KIII β) and *Saccharomyces cerevisiae* (PIK1) forms of the Golgi regulator phosphatidylinositol 4-kinase also share a common 14-3-3-binding site [14,50].

We note that plants, which have their own history of whole-genome duplications, also have multiple 14-3-3s [51] and 14-3-3-binding proteins belonging to multi-protein families [52,53]. It would be interesting to discover whether there are mechanistic parallels between the evolution of vertebrate and plant 14-3-3-interactomes. *Saccharomyces cerevisiae* has also been through a WGD [54], raising the question of how this event influenced the evolution of its two 14-3-3 proteins and their phosphoprotein targets.

4.2. Case study of a disease-linked 14-3-3-binding 2R-ohnologue family: the REEP proteins

Here, 103 candidate lynchpins were identified, defined as 14-3-3-binding sites that are conserved across members of a human 2R-ohnologue family, and which align with Ser/Thr residues in the single pro-orthologues in the basal invertebrates of our chordate lineage (electronic supplementary material, figure S4). However, while sequence alignments are useful, only the type of biochemical analyses performed here for the REEP proteins can define 14-3-3-binding phosphosites with confidence.

Interestingly, 46 per cent (100/216) of experimentally defined 14-3-3-binding phosphosites and 47 per cent (49/103) of the potential 14-3-3-binding lynchpins have a phosphorylatable serine in the -2 position (see electronic supplementary material, figure S2 and table S2) [14,55], including that in the REEP 1–4 family (figure 7b). The REEP lynchpin (phosphoSer152 in REEP4) evolved in a step-wise manner with the basic residues being in place first, then a potential 14-3-3-binding site was formed before the 2R-WGD event, thereby making phosphoSer152 a potential lynchpin. The -2 serine (phosphoSer150 in REEP4) is in some, but not all, bilaterian invertebrate REEP proteins. This feature will require further work to define the relevant kinases and regulatory significance of the juxtaposed phosphoSer residues.

As well as acting as a lynchpin 14-3-3-binding site, the Ser152 region of REEP4 is involved in interactions with the RAB3GAP1–RAB3GAP2 heterodimer, which is a GTPase-activating protein for Rab3 that mediates neurotransmitter release. However, REEP4 cannot bind to 14-3-3 and to RAB3GAP1–RAB3GAP2 at the same time. Mutation of REEP1 causes hereditary spastic paraplegia 31 in humans, which is characterized by progressive weakness and stiffness of the legs, and mutation of REEP4 causes lower body paralysis in an animal model [31,32,56]. Mutations in RAB3GAP1 and RAB3GAP2 cause the autosomal recessive Warburg Micro and Martsof syndromes, which involve congenital cataracts, microphthalmia, postnatal microcephaly and developmental delay [38–40]. It is intriguing to find a molecular connection between these two types of disorder. Regulated membrane trafficking is a molecular theme. One hypothesis is that REEP4 and related proteins are involved in trafficking of synaptic vesicles towards the ends of axons, during which events the REEP4 undergoes a phosphorylation-dependent switch that determines whether it binds to 14-3-3s or engages with RAB3GAP1–RAB3GAP2 to modulate Rab3-mediated neurotransmitter release. The motor neurons that run from the brainstem to connect with the lower motor neurons would be vulnerable to long-distance trafficking problems (consistent with the REEP mutations causing paraplegia), whereas many neurons would be affected by neurotransmitter release problems (consistent with Warburg Micro and Martsof syndromes). It is unclear how the motor function of REEP proteins relates to the separate literature on how REEPs regulate cell surface expression of odourant and taste receptors [34], though mechanisms controlling sensory inputs and vertebrate motion may be evolutionarily linked [57].

The *KDM3B* (*JMJD1B*), *REEP2*, *EGR1* and *CTNNA1* genes lie within the MDS 5q31.2 CDR1 microdeletion region that is linked to the aggressive form of MDS and acute myeloid leukaemia [35,58–60], and this region also constitutes a 2R-WGD paralogon (figure 4). Within the conceptual framework of MIMO systems, it is interesting that peripheral neuropathy is a phenotype shared by hereditary spastic paraplegia 31 (REEP1) and MDS with 5q31.2 deletion (REEP2). These considerations suggest a case for examining whether REEP2 contributes to the aetiology of MDS.

4.3. The MIMO imbalance disease hypothesis

The 2R-ohnologues were previously reported to be enriched in disease genes [2–4]. Indeed, the 14-3-3s are themselves linked to diseases: chromosome deletions including the 14-3-3 epsilon gene result in craniofacial dysmorphisms, brainstem reduction in 14-3-3 protein levels has been identified in sudden infant death syndrome, and certain cancers involve changes in expression of specific 14-3-3s. Also, many 14-3-3-binding 2R-ohnologues are linked to disease, including cancer (the protein kinase B-Raf, E3 ubiquitin ligase mdm2, tumour suppressor p53/TP53 and transcription factor MITF), metabolic disorders (AS160, TBC1D1), movement disorders (ataxin-1, REEP1, protein kinase LRRK2) and developmental RASopathies (disorders linked to the Ras pathway; C-Raf and E3 ubiquitin ligase Cbl) [61–63].

It makes sense to suppose that if a critical regulatory function were performed by a single protein in an animal like amphioxus, then its mutation might be lethal. In contrast, mutation or loss of one or other component of a delicately

balanced MIMO system might not be lethal if other proteins of the family can at least partially compensate for the function (figure 7c). However, the loss of a regulatory input may make the function become uncoordinated with other cellular processes, thereby causing the debilitating disorder.

While it was previously stated that disease is generally linked with just one member of any given 2R-ohnologue family [4], the situation appears to be more complicated, with mutations in different protein family members giving rise to different diseases, as has been discussed here for the REEP family. Another multi-disorder family is the Raf kinases, comprising B-Raf, A-Raf and C-Raf/Raf-1. B-Raf is mutated to an active V600E form in approximately 50 per cent of melanomas, and drugs that inhibit B-Raf-V600E have clinical efficacy [64]. However, when the patient also has cells with activated Ras, the drug-inhibited B-Raf interacts with other Raf proteins, facilitating their activation via Ras, which may promote tumour growth [65,66]. The activation of C-Raf/Raf-1 by Ras can be inhibited by 14-3-3 binding to protein kinase A-phosphorylated sites on C-Raf/Raf-1 [67]. Moreover, mutations that impair 14-3-3 binding to C-Raf, and hence promote its activation, cause developmental RASopathies (including the pSer259 14-3-3-binding phosphosite and Ser257, which we note is a phosphorylatable -2 serine residue) [68,69].

The REEP and Raf examples illustrate how the increased complexity of MIMO-based systems has gone hand-in-hand with increased vulnerability to disease during embryogenesis and adulthood, and emphasize that the study of 'single gene' diseases should take account of the potential interplay between the disease protein and other members of its 2R-ohnologue family.

Finally, over the evolutionary time-scale, variations in the signalling configurations of MIMO systems could also help explain the variety of species of mammals, reptiles, birds, amphibians and fish. For example, we were interested to notice that REEP4 is missing from fish, while IRS3 (insulin receptor substrate 3) is a pseudogene in humans, but is a functional gene in mice. In other words, genetic disorders and genetic variety are on the same continuum. It will be fascinating to compare the patterns of 2R-ohnologue loss and retention in different vertebrates, and try to relate these patterns to the special features of each lineage.

5. Material and methods

5.1. Gold and silver 14-3-3-binding proteins

The list of 'gold standard' mammalian proteins for which 14-3-3-binding sites were reported up to August 2010 [14,24] was revised and updated to August 2011. A list of 'silver standards' was also prepared from the literature, meaning proteins demonstrated to display direct and phosphorylation-dependent binding to 14-3-3s, but where phosphorylated residues were not identified. Relevant references are cited in electronic supplementary material, table S1.

5.2. Protein mapping

The datasets from Makino & McLysaght [2] and Huminiecki & Heldin [3] were used to define the ohnologue families. Both papers used Ensembl identifiers. The Biomart tool at Ensembl

(<http://www.ensembl.org/biomart/martview/>) was used to create a table with Ensembl Gene ID (Ensembl Gene 65, *Homo sapiens* genes GRCh37.p5) and UniProt IDs (UniProt/SwissProt ID, UniProt/SwissProt Accession). The table was implemented as a dictionary in a python script to map the Ensembl identifiers onto UniProt IDs. The dataset of Huminiecki & Heldin [3] (see electronic supplementary material, table S1) clusters ohnologue families using the TreeFam ID as identifier, and no further steps were required. The ohnologue pairs from electronic supplementary material, table S1, worksheet 7 of Makino & McLysaght [2] were clustered into families and the family size computed with a python script. A progressive number was used as family identifier. A second python script was used to create a VisANT XML file to group each 'node' protein of electronic supplementary material, table S3 into the correspondent ohnologue family 'group'.

5.3. Genetic association of diseases

The gold and silver standard proteins were assigned to the relevant diseases based on data in electronic supplementary material, tables S4a (for human) and S5a (for mouse) of Zhang *et al.* [70] (also see [28]). The gene2accession table from NCBI (<ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/>) was used to create a python dictionary to convert the gene name to the Gene Identifiers and UniProt IDs. The BioMart service at Ensembl was used to retrieve the human homologues of the mouse UniProt accession IDs (two proteins were defined as homologues if they share 80% amino acid identity). The OMIM diseases were retrieved using the DAVID resource (<http://david.abcc.ncifcrf.gov/>). The disease classes (manually assigned) are based on Zhang *et al.* [70].

5.4. Biochemical analyses

Biochemical analyses of REEP-GFP proteins used the methods reported in Johnson *et al.* [24]. HEK293 cells cultured in medium containing 10 per cent (v/v) foetal bovine serum were transfected with plasmids to express REEP4-GFP (wild-type) and REEP4-S152A-GFP, as indicated. After 24 h, cells were serum-starved for 8 h, then stimulated with epidermal growth factor (EGF, 100 ng ml⁻¹ for 15 min), phorbol-12-myristate-13-acetate (PMA, 100 ng ml⁻¹ for 30 min) and adenylate cyclase activator forskolin (20 µM for 30 min), as indicated. Where shown, cells were incubated with p90 ribosomal S6 kinase (p90RSK) inhibitor BI-D1870 (10 µM for 30 min), pan-PKC inhibitor (Gö6983, 1 µM for 30 min), Gö6976 (which inhibits PKCα and PKCβ1, but not PKCδ, -ε or -ζ; 1 µM for 30 min) and non-specific protein kinase A inhibitor H-89 (30 µM for 30 min) prior to stimulation. REEP4-GFP was isolated from cell lysates (2.5 mg) using GFP-Trap agarose, and analysed. Antibodies that specifically recognize human REEP4 phosphorylated on Ser152 were raised in sheep against the synthetic phosphopeptide AGRLRSF(s)MQDLRC (residues 145–157, where lower case 's' denotes phosphoSer152, plus Cys for coupling; ref. S500B, second bleed used).

6. Acknowledgements

This work was supported by the UK Medical Research Council via a Developmental Pathway Funding

Scheme award; companies who support the Division of Signal Transduction Therapy (DSTT) at the University of Dundee, namely AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono and Pfizer; and a Research Councils UK fellowship in marine biology to D.E.K.F. We thank the antibody purification team of the DSTT, coordinated by Hilary McLaulchlan and James Hastie, David Campbell for mass

spectrometric analyses, Kirsten Mcleod and Janis Stark for tissue culture support, Alisdair Mclean for critical reading and Rachel Naismith for secretarial assistance. M.T., C.J., D.E.K.F. and C.M. conceived and designed the study; M.T., D.E.K.F. and C.M. performed the computational analyses; C.J. and R.T. performed biochemical studies; C.M. drafted the manuscript and coordinated its revision.

References

- Putnam NH *et al.* 2008 The amphioxus genome and the evolution of the chordate karyotype. *Nature* **453**, 1064–1071. (doi:10.1038/nature06967)
- Makino T, McLysaght A. 2010 Ohnologs in the human genome are dosage balanced and frequently associated with disease. *Proc. Natl Acad. Sci. USA* **107**, 9270–9274. (doi:10.1073/pnas.0914697107)
- Huminiecki L, Heldin CH. 2010 2R and remodeling of vertebrate signal transduction engine. *BMC Biol.* **8**, 146. (doi:10.1186/1741-7007-8-146)
- Dickerson JE, Robertson DL. 2011 On the origins of Mendelian disease genes in man: the impact of gene duplication. *Mol. Biol. Evol.* **29**, 61–69. (doi:10.1093/molbev/msr111)
- Bauer-Mehren A, Bundschuh M, Rautschka M, Mayer MA, Sanz F, Furlong LI. 2011 Gene-disease network analysis reveals functional modules in Mendelian, complex and environmental diseases. *PLoS ONE* **6**, e20284. (doi:10.1371/journal.pone.0020284)
- Farre D, Alba MM. 2010 Heterogeneous patterns of gene-expression diversification in mammalian gene duplicates. *Mol. Biol. Evol.* **27**, 325–335. (doi:10.1093/molbev/msp242)
- Levitt M. 2009 Nature of the protein universe. *Proc. Natl Acad. Sci. USA* **106**, 11 079–11 084. (doi:10.1073/pnas.0905029106)
- Wang Z, Ding G, Geistlinger L, Li H, Liu L, Zeng R, Tateno Y, Li Y. 2011 Evolution of protein phosphorylation for distinct functional modules in vertebrate genomes. *Mol. Biol. Evol.* **28**, 1131–1140. (doi:10.1093/molbev/msq268)
- Holt LJ, Tuch BB, Villen J, Johnson AD, Gygi SP, Morgan DO. 2009 Global analysis of Cdk1 substrate phosphorylation sites provides insights into evolution. *Science* **325**, 1682–1686. (doi:10.1126/science.1172867)
- Tan CS *et al.* 2009 Comparative analysis reveals conserved protein phosphorylation networks implicated in multiple diseases. *Sci. Signal.* **2**, ra39. (doi:10.1126/scisignal.2000316)
- Schweiger R, Linal M. 2010 Cooperativity within proximal phosphorylation sites is revealed from large-scale proteomics data. *Biol. Direct* **5**, 6. (doi:10.1186/1745-6150-5-6)
- Dinkel H, Chica C, Via A, Gould CM, Jensen LJ, Gibson TJ, Diella F. 2011 Phospho.ELM: a database of phosphorylation sites—update 2011. *Nucleic Acids Res.* **39**, D261–D267. (doi:10.1093/nar/gkq1104)
- Freschi L, Courcelles M, Thibault P, Michnick SW, Landry CR. 2011 Phosphorylation network rewiring by gene duplication. *Mol. Syst. Biol.* **7**, 504. (doi:10.1038/msb.2011.43)
- Johnson C, Crowther S, Stafford MJ, Campbell DG, Toth R, Mackintosh C. 2010 Bioinformatic and experimental survey of 14-3-3-binding sites. *Biochem. J.* **427**, 69–78. (doi:10.1042/BJ20091834)
- Silhan J, Vacha P, Strnadova P, Vecer J, Herman P, Sulc M, Teisinger J, Obsilova V, Obsil T. 2009 14-3-3 protein masks the DNA binding interface of forkhead transcription factor FOXO4. *J. Biol. Chem.* **284**, 19 349–19 360. (doi:10.1074/jbc.M109.002725)
- Yaffe MB. 2002 How do 14-3-3 proteins work?—gatekeeper phosphorylation and the molecular anvil hypothesis. *FEBS Lett.* **513**, 53–57. (doi:10.1016/S0014-5793(01)03288-4)
- Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, Gamblin SJ, Smerdon SJ, Cantley LC. 1997 The structural basis for 14-3-3:phosphopeptide binding specificity. *Cell* **91**, 961–971. (doi:10.1016/S0092-8674(00)80487-0)
- Zhu G, Fujii K, Belkina N, Liu Y, James M, Herrero J, Shaw S. 2005 Exceptional disfavor for proline at the P+1 position among AGC and CAMK kinases establishes reciprocal specificity between them and the proline-directed kinases. *J. Biol. Chem.* **280**, 10 743–10 748. (doi:10.1074/jbc.M413159200)
- Chen S, Synowsky S, Tinti M, Mackintosh C. 2011 The capture of phosphoproteins by 14-3-3 proteins mediates actions of insulin. *Trends Endocrinol. Metab.* **22**, 429–436. (doi:10.1016/j.tem.2011.07.005)
- Ramm G, Larance M, Guilhaus M, James DE. 2006 A role for 14-3-3 in insulin-stimulated GLUT4 translocation through its interaction with the RabGAP AS160. *J. Biol. Chem.* **281**, 29 174–29 180. (doi:10.1074/jbc.M603274200)
- Chen S, Murphy J, Toth R, Campbell DG, Morrice NA, MacKintosh C. 2008 Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. *Biochem. J.* **409**, 449–459. (doi:10.1042/BJ20071114)
- Frosig C, Pehmoller C, Birk JB, Richter EA, Wojtaszewski JF. 2010 Exercise-induced TBC1D1 Ser237 phosphorylation and 14-3-3 protein binding capacity in human skeletal muscle. *J. Physiol.* **588**, 4539–4548. (doi:10.1113/jphysiol.2010.194811)
- Chen S, Wasserman DH, Mackintosh C, Sakamoto K. 2011 Mice with AS160/TBC1D4-Thr649Ala knockin mutation are glucose intolerant with reduced insulin sensitivity and altered GLUT4 trafficking. *Cell Metab.* **13**, 68–79. (doi:10.1016/j.cmet.2010.12.005)
- Johnson C *et al.* 2011 Visualization and biochemical analyses of the emerging mammalian 14-3-3-phosphoproteome. *Mol. Cell Proteomics* **10**, M110005751. (doi:10.1074/mcp.M110.005751)
- Momand J, Villegas A, Belyi VA. 2011 The evolution of MDM2 family genes. *Gene*. **486**, 23–30. (doi:10.1016/j.gene.2011.06.030)
- Zhao ZM, Reynolds AB, Gaucher EA. 2011 The evolutionary history of the catenin gene family during metazoan evolution. *BMC Evol. Biol.* **11**, 198. (doi:10.1186/1471-2148-11-198)
- Wang Y, Chen K, Yao Q, Zheng X, Yang Z. 2009 Phylogenetic analysis of zebrafish basic helix-loop-helix transcription factors. *J. Mol. Evol.* **68**, 629–640. (doi:10.1007/s00239-009-9232-7)
- Hilman D, Gat U. 2011 The evolutionary history of YAP and the Hippo/YAP pathway. *Mol. Biol. Evol.* **28**, 2403–2417. (doi:10.1093/molbev/msr065)
- Pavlicek J *et al.* 2010 Evolution of AANAT: expansion of the gene family in the cephalochordate amphioxus. *BMC Evol. Biol.* **10**, 154. (doi:10.1186/1471-2148-10-154)
- Hu Z, Hung JH, Wang Y, Chang YC, Huang CL, Huyck M, DeLisi C. 2009 VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene ontology. *Nucleic Acids Res.* **37**, W115–W121. (doi:10.1093/nar/gkp406)
- Zuchner S, Wang G, Tran-Viet KN, Nance MA, Gaskell PC, Vance JM, Ashley-Koch AE, Pericak-Vance MA. 2006 Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. *Am. J. Hum. Genet.* **79**, 365–369. (doi:10.1086/505361)
- Argasinska J, Rana AA, Gilchrist MJ, Lachani K, Young A, Smith JC. 2009 Loss of REEP4 causes paralysis of the *Xenopus* embryo. *Int. J. Dev. Biol.* **53**, 37–43. (doi:10.1387/ijdb.072542ja)
- Park SH, Zhu PP, Parker RL, Blackstone C. 2010 Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network. *J. Clin. Invest.* **120**, 1097–1110. (doi:10.1172/JCI40979)
- Ilegems E, Iwatsuki K, Kokrashvili Z, Benard O, Ninomiya Y, Margolskee RF. 2010 REEP2 enhances sweet receptor function by recruitment to lipid rafts. *J. Neurosci.* **30**, 13 774–13 783. (doi:10.1523/JNEUROSCI.0091-10.2010)

35. MacKinnon RN, Kannourakis G, Wall M, Campbell LJ. 2011 A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes. *Cancer Genet.* **204**, 187–194. (doi:10.1016/j.cancergen.2011.02.001)
36. Catchen JM, Conery JS, Postlethwait JH. 2009 Automated identification of conserved synteny after whole-genome duplication. *Genome Res.* **19**, 1497–1505. (doi:10.1101/gr.090480.108)
37. Telford MJ, Copley RR. 2011 Improving animal phylogenies with genomic data. *Trends Genet.* **27**, 186–195. (doi:10.1016/j.tig.2011.02.003)
38. Borck G *et al.* 2011 A homozygous RAB3GAP2 mutation causes Warburg Micro syndrome. *Hum. Genet.* **129**, 45–50. (doi:10.1007/s00439-010-0896-2)
39. Corbeel L, Freson K. 2008 Rab proteins and Rab-associated proteins: major actors in the mechanism of protein-trafficking disorders. *Eur. J. Pediatr.* **167**, 723–729. (doi:10.1007/s00431-008-0740-z)
40. Aligianis IA *et al.* 2006 Mutation in Rab3 GTPase-activating protein (RAB3GAP) noncatalytic subunit in a kindred with Martsolf syndrome. *Am. J. Hum. Genet.* **78**, 702–707. (doi:10.1086/502681)
41. Perez-Bercoff A, Makino T, McLysaght A. 2010 Duplicability of self-interacting human genes. *BMC Evol. Biol.* **10**, 160. (doi:10.1186/1471-2148-10-160)
42. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. 1996 Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. *FEBS Lett.* **399**, 333–338. (doi:10.1016/S0014-5793(96)01370-1)
43. Dong J *et al.* 2007 Elucidation of a universal size-control mechanism in *Drosophila* and mammals. *Cell* **130**, 1120–1133. (doi:10.1016/j.cell.2007.07.019)
44. Dubois F, Vandermoere F, Gernez A, Murphy J, Toth R, Chen S, Geraghty KM, Morrice NA, MacKintosh C. 2009 Differential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signaling. *Mol. Cell Proteomics* **8**, 2487–2499. (doi:10.1074/mcp.M800544-MCP200)
45. Larance M, Rowland AF, Hoehn KL, Humphreys DT, Preiss T, Guilhaus M, James DE. 2010 Global phosphoproteomics identifies a major role for AKT and 14-3-3 in regulating EDC3. *Mol. Cell Proteomics* **9**, 682–694. (doi:10.1074/mcp.M900435-MCP200)
46. Hou Z, Peng H, White DE, Wang P, Lieberman PM, Halazonetis T, Rauscher III, FJ. 2010 14-3-3 binding sites in the snail protein are essential for snail-mediated transcriptional repression and epithelial-mesenchymal differentiation. *Cancer Res.* **70**, 4385–4393. (doi:10.1158/0008-5472.CAN-10-0070)
47. Bronisz A, Sharma SM, Hu R, Godlewski J, Tzivion G, Mansky KC, Ostrowski MC. 2006 Microphthalmia-associated transcription factor interactions with 14-3-3 modulate differentiation of committed myeloid precursors. *Mol. Biol. Cell* **17**, 3897–3906. (doi:10.1091/mbc.E06-05-0470)
48. Tang SJ, Suen TC, McInnes RR, Buchwald M. 1998 Association of the TLX-2 homeodomain and 14-3-3 η signaling proteins. *J. Biol. Chem.* **273**, 25 356–25 363. (doi:10.1074/jbc.273.39.25356)
49. Dissanayake K, Toth R, Blakey J, Olsson O, Campbell DG, Prescott AR, MacKintosh C. 2011 ERK/p90(RSK)/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capicua. *Biochem. J.* **433**, 515–525. (doi:10.1042/BJ20101562)
50. Demmel L *et al.* 2008 Nucleocytoplasmic shuttling of the Golgi phosphatidylinositol 4-kinase Pik1 is regulated by 14-3-3 proteins and coordinates Golgi function with cell growth. *Mol. Biol. Cell* **19**, 1046–1061. (doi:10.1091/mbc.E07-02-0134)
51. Rosenquist M, Sehnke P, Ferl RJ, Sommarin M, Larsson C. 2000 Evolution of the 14-3-3 protein family: does the large number of isoforms in multicellular organisms reflect functional specificity? *J. Mol. Evol.* **51**, 446–458. (doi:10.1007/s002390010107)
52. Castleden CK, Aoki N, Gillespie VJ, MacRae EA, Quick WP, Buchner P, Foyer CH, Furbank RT, Lunn JE. 2004 Evolution and function of the sucrose-phosphate synthase gene families in wheat and other grasses. *Plant Physiol.* **135**, 1753–1764. (doi:10.1104/pp.104.042457)
53. Harthill JE, Meek SE, Morrice N, Pegg MW, Borch J, Wong BH, MacKintosh C. 2006 Phosphorylation and 14-3-3 binding of *Arabidopsis* trehalose-phosphate synthase 5 in response to 2-deoxyglucose. *Plant J.* **47**, 211–223. (doi:10.1111/j.1365-3113X.2006.02780.x)
54. Gordon JL, Byrne KP, Wolfe KH. 2009 Additions, losses, and rearrangements on the evolutionary route from a reconstructed ancestor to the modern *Saccharomyces cerevisiae* genome. *PLoS Genet.* **5**, e1000485. (doi:10.1371/journal.pgen.1000485)
55. Panni S *et al.* 2011 Combining peptide recognition specificity and context information for the prediction of the 14-3-3-mediated interactome in *S. cerevisiae* and *H. sapiens*. *Proteomics* **11**, 128–143. (doi:10.1002/pmic.201000030)
56. Beetz C *et al.* 2008 REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. *Brain* **131**, 1078–1086. (doi:10.1093/brain/awn026)
57. Churcher AM, Taylor JS. 2009 Amphioxus (*Branchiostoma floridae*) has orthologs of vertebrate odorant receptors. *BMC Evol. Biol.* **9**, 242. (doi:10.1186/1471-2148-9-242)
58. Lai F *et al.* 2001 Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). *Genomics* **71**, 235–245. (doi:10.1006/geno.2000.6414)
59. Zhao N, Stoffel A, Wang PW, Eisenbart JD, Espinosa III R, Larson RA, Le Beau MM. 1997 Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1–1.5 Mb and preparation of a PAC-based physical map. *Proc. Natl Acad. Sci. USA* **94**, 6948–6953. (doi:10.1073/pnas.94.13.6948)
60. Boulwood J, Pellagatti A, McKenzie AN, Wainscoat JS. 2010 Advances in the 5q- syndrome. *Blood* **116**, 5803–5811. (doi:10.1182/blood-2010-04-273771)
61. Wood NT, Meek DW, MacKintosh C. 2009 14-3-3 Binding to Pim-phosphorylated Ser166 and Ser186 of human Mdm2—potential interplay with the PKB/Akt pathway and p14(ARF). *FEBS Lett.* **583**, 615–620. (doi:10.1016/j.febslet.2009.01.003)
62. Nagamani SC *et al.* 2009 Microdeletions including YWHAE in the Miller–Dieker syndrome region on chromosome 17p13.3 result in facial dysmorphisms, growth restriction, and cognitive impairment. *J. Med. Genet.* **46**, 825–833. (doi:10.1136/jmg.2009.067637)
63. Broadbelt KG *et al.* 2011 Brainstem deficiency of the 14-3-3 regulator of serotonin synthesis: a proteomics analysis in the sudden infant death syndrome. *Mol. Cell Proteomics*. (doi:10.1074/mcp.M111.009530)
64. Bollag G *et al.* 2010 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature* **467**, 596–599. (doi:10.1038/nature09454)
65. Hatzivassiliou G *et al.* 2010 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature* **464**, 431–435. (doi:10.1038/nature08833)
66. Halaban R *et al.* 2010 PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. *Pigment Cell Melanoma Res.* **23**, 190–200. (doi:10.1111/j.1755-148X.2010.00685.x)
67. Dumaz N, Marais R. 2003 Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. *J. Biol. Chem.* **278**, 29 819–29 823. (doi:10.1074/jbc.C300182200)
68. Molzan M *et al.* 2010 Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. *Mol. Cell Biol.* **30**, 4698–4711. (doi:10.1128/MCB.01636-09)
69. Kobayashi T *et al.* 2010 Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. *Hum. Mutat.* **31**, 284–294. (doi:10.1002/humu.21187)
70. Zhang Y, De S, Garner JR, Smith K, Wang SA, Becker KG. 2010 Systematic analysis, comparison, and integration of disease based human genetic association data and mouse genetic phenotypic information. *BMC Med. Genomics* **3**, 1. (doi:10.1186/1755-8794-3-1)